氟哌啶醇,临床注释-2,变异和临床注释数据

氟哌啶醇

临床注释ID

1183631061

药物名称(英)

haloperidol

变异单倍型

CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*17

基因

CYP2D6

证据级别

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Metabolism/PK

表现型类别

代谢/PK

分数

107.4375

PMID计数

计数的证据

表现型

精神分裂症

表现型(英)

Schizophrenia

最新日期

2021/5/3 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/1183631061

专业人口(英)

Pediatric

专业人口

儿科

临床等位基因

id	等位基因	注释文本
636	*17	The CYP2D617 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the 17 allele in combination with a decreased or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.
635	*10	The CYP2D610 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the 10 allele in combination with a decreased or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the 10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the 10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.
634	*5	The CYP2D65 allele has been assigned as a no function allele by CPIC. Patients carrying the 5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the 5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the 5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.
633	*4	The CYP2D64 allele has been assigned as a no function allele by CPIC. Patients carrying the 4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the 4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the 4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.
632	*3	The CYP2D63 allele has been assigned as a no function allele by CPIC. Patients carrying the 3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the 3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the 3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.
631	*2	The CYP2D62 allele is assigned as a normal function allele by CPIC. Patients carrying the 2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of haloperidol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of haloperidol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of haloperidol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.
630	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the 1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of haloperidol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of haloperidol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of haloperidol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.

临床证据

id	证据的ID	总结
1002	1183623024	CYP2D6 2 + 10 are not associated with increased metabolism of haloperidol as compared to CYP2D6 *1.
1001	1183622259	CYP2D6 3 + 4 are associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.
1000	1183630934	CYP2D6 1/10 + 17/17 are not associated with decreased metabolism of haloperidol in healthy individuals as compared to CYP2D6 1/1.
999	1183629904	CYP2D6 5 + 10 are associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.
998	1449189048	CYP2D6 1xN is associated with extrapyramidal symptoms, hepatic cytolysis and Weight gain when exposed to haloperidol, levomepromazine and risperidone in children with Schizophrenia as compared to CYP2D6 1.
997	1447677749	CYP2D6 10/10 is associated with increased concentrations of haloperidol in people with Schizophrenia as compared to CYP2D6 1/1 + 1/10.
996	1447677736	CYP2D6 2/2 is associated with increased concentrations of haloperidol in people with Schizophrenia as compared to CYP2D6 1/1 + 1/2.
995	1183630925	CYP2D6 4/4 is associated with decreased metabolism of haloperidol in healthy individuals as compared to CYP2D6 1/1 + 1/4.
994	1183630106	CYP2D6 10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 1.
993	1183629922	CYP2D6 5 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 1.
992	1183629749	CYP2D6 10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 1.
991	1183629618	CYP2D6 10 is not associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 1.
990	1183624234	CYP2D6 10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 1.
989	1183623471	CYP2D6 5 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 1.
988	1183623462	CYP2D6 2 is not associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 1.
987	1183623437	CYP2D6 10 is not associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 1.
986	1183622774	CYP2D6 10/10 is not associated with decreased metabolism of haloperidol as compared to CYP2D6 1/1 + 1/10.
985	1447682070	CYP2D6 poor metabolizer is not associated with concentrations of haloperidol, paliperidone or zuclopenthixol in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.
984	1448993570	CYP2D6 poor metabolizer genotype is associated with increased dose-adjusted trough concentrations of haloperidol in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer genotype.
983	PA166104988	Annotation of DPWG Guideline for haloperidol and CYP2D6

临床病史

id	类型	评论
868	Update	Checked.
867	Update	Removed duplicate VAs
866	Update	Added DPWG guideline as evidence and rewrote phenotype descriptions to fit LOE 1A template. CA requires independent curator check before approval.
865	Update	CA score added as part of scoring system release. LOE may have automatically changed based on new score but may be subject to further changes upon curator review.
864	Update	Added PMID 29472872

最新招商产品更多>>